In 2023, Pfizer published research papers successively, reporting the results of randomized clinical trials on the efficacy and safety of PF-06882961 for blood sugar control in patients with type 2 diabetes, the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06882961 in Japanese adults with type 2 diabetes from a phase 1 clinical trial, and the results of a 12-week randomized, placebo-controlled, dose-escalation phase 2 trial on the tolerability, safety, and pharmacodynamics of PF-06882961 for the treatment of type 2 diabetes
Higher concentrations may increase results but also increase irritation risk
Pressing the plunger too forcefully can also create additional tissue trauma
This fast-absorbing liquid supplement is ideal for individuals looking to manage weight, enhance endurance, and improve workout recovery